Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease

About this item

Title

Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease

Content partner

University of Otago

Collection

Otago University Research Archive

Description

Anti-TNF prevents postoperative Crohn's disease recurrence in most patients but not all. This study aimed to define the relationship between adalimumab pharmacokinetics, maintenance of remission and recurrence. As part of a study of postoperative Crohn's disease management, some patients undergoing resection received prophylactic postoperative adalimumab. In these patients, serum and fecal adalimumab concentration and serum anti-adalimumab antibodies [AAAs] were measured at 6, 12 and 18 month...

Read more

Format

Research paper

Research format

Scholarly text / Journal article

Thesis level

Article

Date created

2018-05-25

Creator

Wright, Emily K / Kamm, Michael A / De Cruz, Peter / Hamilton, Amy L / Selvaraj, Fabiyola / Princen, Fred / Gorelik, Alexandra / Liew, Danny / Prideaux, Lani / Lawrance, Ian C / Andrews, Jane M / Bampton, Peter A / Jakobovits, Simon L / Florin, Timothy H / Gibson, Peter R / Debinski, Henry / Macrae, Finlay A / Samuel, Douglas / Kronborg, Ian / Radford-Smith, Graham / Gearry, Richard B / Selby, Warwick / Bell, Sally J / Brown, Steven J / Connell, William R

URL

https://hdl.handle.net/10523/28563

Related subjects

Adalimumab - blood / Adalimumab - immunology / Adalimumab - pharmacokinetics / Adalimumab - therapeutic use / Adult / Anti-Inflammatory Agents - blood / Anti-Inflammatory Agents - immunology / Anti-Inflammatory Agents - pharmacokinetics / Anti-Inflammatory Agents - therapeutic use / Antibodies - blood / Crohn Disease - blood / Crohn Disease - complications / Crohn Disease - drug therapy / Crohn Disease - surgery / Drug Monitoring / Feces - chemistry / Female / Humans / Immunosuppressive Agents - therapeutic use / Leukocyte L1 Antigen Complex - analysis / Male / Middle Aged / Obesity - blood / Obesity - complications / Postoperative Period / Recurrence / Secondary Prevention / Severity of Illness Index / Tumor Necrosis Factor-alpha - antagonists & inhibitors / Young Adult

What is the copyright status of this item?

All Rights Reserved

This item is all rights reserved, which means you'll have to get permission from University of Otago before using it.

What can I do with this item?

You must always check with University of Otago to confirm the specific terms of use, but this is our understanding:

Non-infringing use

NZ Copyright law does not prevent every use of a copyright work. You should consider what you can and cannot do with a copyright work.

No sharing

You may not copy and/or share this item with others without further permission. This includes posting it on your blog, using it in a presentation, or any other public use.

No modifying

You are not allowed to adapt or remix this item into any other works.

No commercial use

You may not use this item commercially.